264 related articles for article (PubMed ID: 29870627)
1. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
[TBL] [Abstract][Full Text] [Related]
2. [Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke].
Pásztor M; Bereczki D; Szakács Z; May Z
Ideggyogy Sz; 2017 Jul; 70(7-8):284-288. PubMed ID: 29870643
[TBL] [Abstract][Full Text] [Related]
3. Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series.
Peacock WF; Grotta JC; Steiner T
J Emerg Med; 2019 Dec; 57(6):e167-e173. PubMed ID: 31662218
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
5. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Althaus K; Berrouschot J; Cangür H; Daffertshofer M; Edelbusch S; Gröschel K; Haase CG; Harloff A; Held V; Kauert A; Kraft P; Lenz A; Müllges W; Obermann M; Partowi S; Purrucker J; Ringleb PA; Röther J; Rossi R; Schäfer N; Schneider A; Schuppner R; Seitz RJ; Szabo K; Wruck R
Int J Stroke; 2017 Jun; 12(4):383-391. PubMed ID: 28494694
[TBL] [Abstract][Full Text] [Related]
6. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
7. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
Giustozzi M; Verso M; Agnelli G; Becattini C
J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
[TBL] [Abstract][Full Text] [Related]
8. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
Sheikh-Taha M
Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
[TBL] [Abstract][Full Text] [Related]
9. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
Lindeman E
Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.
Lu VM; Phan K; Rao PJ; Sharma SV; Kasper EM
Clin Neurol Neurosurg; 2019 Jun; 181():76-81. PubMed ID: 31015061
[TBL] [Abstract][Full Text] [Related]
11. Idarucizumab: The Antidote for Reversal of Dabigatran.
Eikelboom JW; Quinlan DJ; van Ryn J; Weitz JI
Circulation; 2015 Dec; 132(25):2412-22. PubMed ID: 26700008
[No Abstract] [Full Text] [Related]
12. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
13. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
Boda Z
Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
[TBL] [Abstract][Full Text] [Related]
14. Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab.
Braemswig TB; Eschenfelder CC; Nolte CH
Am J Emerg Med; 2017 Apr; 35(4):662.e3-662.e4. PubMed ID: 27836320
[TBL] [Abstract][Full Text] [Related]
15. Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report.
Facchinetti R; DeGuidi G; Pitoni F; Ricci G; Lippi G
Blood Coagul Fibrinolysis; 2017 Oct; 28(7):576-579. PubMed ID: 28362649
[TBL] [Abstract][Full Text] [Related]
16. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.
Šaňák D; Jakubíček S; Černík D; Herzig R; Kunáš Z; Mikulík R; Ostrý S; Reif M; Rohan V; Tomek A; Veverka T
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2479-2483. PubMed ID: 29807757
[TBL] [Abstract][Full Text] [Related]
18. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
[TBL] [Abstract][Full Text] [Related]
19. Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.
Hieber M; Hollasch H; Heck D; Mächtel M; Geisen U; Niesen WD; Brich J; Harloff A
J Thromb Thrombolysis; 2018 Jul; 46(1):12-15. PubMed ID: 29633066
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA; Kuyumjian Y; Eaves S; Dollard E
J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
